Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kymera Therapeutics, Inc. KYMR
$27.85
-$0.33 (-1.17%)
На 18:03, 12 мая 2023
+66.36%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1524928538.00000000
-
week52high
39.85
-
week52low
13.15
-
Revenue
46826000
-
P/E TTM
-11
-
Beta
1.71712800
-
EPS
-2.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 15 авг 2022 г. | |
| Credit Suisse | Outperform | Outperform | 10 авг 2022 г. |
| Goldman Sachs | Buy | 03 авг 2022 г. | |
| SVB Leerink | Market Perform | 20 июл 2022 г. | |
| Wells Fargo | Overweight | Overweight | 01 июн 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 29 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 04 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 08 ноя 2022 г. |
| Raymond James | Market Perform | 08 ноя 2022 г. | |
| Wells Fargo | Overweight | Overweight | 03 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 19 дек 2022 г. |
| Goldman Sachs | Buy | Buy | 16 дек 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 15 дек 2022 г. |
| Credit Suisse | Neutral | Outperform | 06 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | A | 1888351 | 15912 | 12 янв 2023 г. |
| BVF PARTNERS L P/IL | A | 2494688 | 2985 | 12 янв 2023 г. |
| Booth Bruce | D | 890148 | 21592 | 12 янв 2023 г. |
| Booth Bruce | D | 4968114 | 77128 | 12 янв 2023 г. |
| Atlas Venture Fund X, L.P. | D | 890148 | 21592 | 12 янв 2023 г. |
| Atlas Venture Fund X, L.P. | D | 4968114 | 77128 | 12 янв 2023 г. |
| BVF PARTNERS L P/IL | A | 1872439 | 11149 | 11 янв 2023 г. |
| BVF PARTNERS L P/IL | A | 2491703 | 10961 | 11 янв 2023 г. |
| Booth Bruce | D | 911740 | 6071 | 11 янв 2023 г. |
| Booth Bruce | D | 5045242 | 21683 | 11 янв 2023 г. |
Новостная лента
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
GlobeNewsWire
01 февр 2023 г. в 07:00
Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
Kymera: Data Derisks Platform, But I Will Wait For More
Seeking Alpha
23 янв 2023 г. в 18:58
Kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did Sanofi's partnering. However, more differentiating data seems to be needed in these indications and with IRAK4 inhibitors.
All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy
Zacks Investment Research
09 янв 2023 г. в 13:33
Kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
GlobeNewsWire
03 янв 2023 г. в 07:00
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 9:00 AM PST. Nello Mainolfi, PhD, Co-Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2023.
7 Perfect Presents to Gift Your 2023 Stock Portfolio
InvestorPlace
21 дек 2022 г. в 16:57
New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations that Feb. and March will see 25 basis point rate hikes, respectively.